Porosome Therapeutics Reports Major Breakthroughs in Alzheimer’s Disease Research
Wednesday, August 06, 2025
Porosome Therapeutics, Inc. has announced significant progress in its novel neurological treatment platform aimed at modifying the course of Alzheimer’s Disease (AD). The company’s approach moves beyond symptom management by directly addressing the underlying biological processes of the disease.
Recent findings include the rapid reduction of Alzheimer’s pathology in human brain organoids treated with the company’s lead therapy. The research also showed a marked decrease in Tau protein levels, a biomarker recognised by the U.S. Food and Drug Administration (FDA) for AD, and led to the development of new classes of potential therapeutics.
Porosome Therapeutics uses a unique strategy known as “Reprogram, Restore, and Rescue”. This involves introducing healthy porosomes—specialised nanomachines responsible for cellular secretion—into damaged neurons. The aim is to repair the cell’s secretory and metabolic functions, which are impaired in Alzheimer’s, thereby tackling the disease at a cellular level.
The company’s treatment method has been validated in human brain organoid models, which are advanced three-dimensional cultures that replicate the structure and activity of the human brain. These models, recommended by the FDA, showed a notable reversal of Alzheimer’s pathology within just two weeks of treatment.
Alongside this, Porosome Therapeutics is employing artificial intelligence (AI) to design proprietary decoy peptides. These peptides are developed to neutralise beta amyloid (1-42), a toxic substance that disrupts protein interactions in neurons and contributes to the decline in neurotransmitter release. The AI-designed peptides bind more effectively to the toxic amyloid, protecting the neuron’s secretory function.
Based on these advancements, the company has classified its therapeutic candidates into three main groups:
- Small Molecules and Peptides – Capable of crossing the blood-brain barrier to restore energy production in brain cells.
- Biologics – Designed to rebuild the porosome complex and correct secretory dysfunction in neurons.
- AI-Designed Peptides – Decoy peptides created through artificial intelligence to block harmful amyloid peptides and safeguard neurotransmission.
These developments have expanded Porosome Therapeutics’ research portfolio and highlight its commitment to pioneering new therapies that move beyond the current standards in Alzheimer’s care. The company is also assessing the possibility of pursuing the FDA’s accelerated approval pathway based on its promising preclinical results.
Source: businesswire.com
